Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 510 KB, PDF document
Metformin is the currently accepted first-line treatment for antipsychotic-associated weight gain (AAWG). However, not all patients benefit from metformin. Glucagon-like peptide-1 receptor agonists (GLP1-RA) have shown promise in the management of obesity in the general population, with preliminary evidence supporting efficacy in AAWG. Semaglutide is a weekly injectable GLP-1RA which received recent approval for obesity management and noted superiority over other GLP-1RAs. This study explored the efficacy and tolerability of semaglutide in AAWG among individuals with severe mental illness. A retrospective chart review of patients treated with semaglutide in the Metabolic Clinic at the Center for Addiction and Mental Health (CAMH) between 2019 and 2021 was conducted. Patients failing a trial of metformin (
Original language | English |
---|---|
Article number | 20451253231165169 |
Journal | Therapeutic Advances in Psychopharmacology |
Volume | 13 |
Number of pages | 10 |
ISSN | 2045-1253 |
DOIs | |
Publication status | Published - 2023 |
- antipsychotics, metformin, obesity, semaglutide, severe mental illness, ONCE-WEEKLY SEMAGLUTIDE, PHASE 3A, OPEN-LABEL, DOUBLE-BLIND, ADD-ON, JAPANESE PATIENTS, DAILY SITAGLIPTIN, ORAL SEMAGLUTIDE, DIABETES CARE, DOUBLE-DUMMY
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
ID: 347979678